Background: An IRB pilot study was done comparing the tissue and serum concentration of cefazolin when one gram was given intravenously against one gram in 250 ml saline injected subcutaneously and dispersed ultrasonically with a power density of 3 watts/cm for one to three minutes using the Mettler ME 800. The phase one study was done on healthy adult women having an elective abdominoplasty. The FDA issued an Investigational New Drug (IND) number for the study because a new method for delivering a drug is considered to be a "new drug." The difference in concentration was so great that a study was done to determine if resistance to cefazolin was concentration-dependent for Methicillin-resistant Staphylococcus aureus (MRSA). The study demonstrated an effective concentration of cefazolin higher than the most resistant strains of MRSA (Figure 1 ). Based upon this finding, under another IRB study, patients who had failed traditional surgical and/or medical treatment were given cefazolin using this experimental method of direct antibiotic delivery.
Conclusion:
Delivery of an antibiotic directly into a localized soft tissue infection without inundating the entire body with an antibiotic has been shown to be highly effective with no negative outcomes. The ability to achieve antibiotic concentrations of up to 1000 times greater than the amount attainable by the use of systemic delivery, with the added effect of increased cell membrane permeability, presents a viable new way to deliver a drug.
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